Taconic Biosciences' Azusa Tanka, PhD was interviewed in this article from Genetic Engineering & Biotechnology News to explain how natural killer (NK) cell therapy can be used to study treatment options using "functional NK cells and an in vivo environment":
Over the past century, a greater understanding of how our immune system recognizes and targets foreign invaders for destruction has emerged, resulting in cancer immunotherapy breakthroughs. Today, more than 900 immunotherapy agents are in clinical development, and more than 1,000 in preclinical development, according to the Cancer Research Institute."
Read the complete article at: GenEngNews.com